Liver cancer awareness month: evolving strategies in immunotherapy and targeted treatment

In this week’s VJOncology podcast, leading experts share the latest updates in the management of hepatocellular carcinoma (HCC) in recognition of Liver Cancer Awareness Month. Stephen Lam Chan, MD, FRCP, discusses emerging immunotherapy and targeted approaches, including novel TIM3 and TIGIT inhibitors, and findings from the SIERRA study of durvalumab and tremelimumab in advanced HCC. Lorenza Rimassa, MD, reviews the CheckMate 9DW trial establishing nivolumab plus ipilimumab as a new standard of care, while Qi Cheng, PhD, highlights promising results from a Phase II study of irpagratinib plus atezolizumab in FGF19-positive HCC. Ciro Celsa, MD, PhD, shares real-world data from the DT-REAL study evaluating durvalumab with or without tremelimumab in unresectable HCC, confirming the regimen’s effectiveness in clinical practice. Finally, Marina Baretti, MD, presents encouraging findings from a Phase I study of a peptide vaccine targeting the DNAJB1-PRKACA fusion in fibrolamellar HCC.